A targeted extracorporeal blood purification procedure that selectively removes pathogenic immunoglobulins and autoantibodies from the patient’s plasma using adsorption columns.
Immunoadsorption (IA) is a form of apheresis in which the patient’s blood is separated into cellular and plasma components. The plasma is then passed through a column containing protein A or antigen-specific ligands that bind immunoglobulins — particularly IgG antibodies — while other plasma proteins are largely preserved and returned to the patient.
Unlike therapeutic plasma exchange, immunoadsorption does not require replacement fluids such as donor plasma or albumin, reducing the risk of allergic reactions and transfusion-related complications.
Blood is drawn from a peripheral or central venous access and passed through a cell separator. The plasma fraction is directed through an adsorption column where immunoglobulins bind to the column matrix. The purified plasma is then recombined with the cellular components and returned to the patient.
Modern immunoadsorption columns can be regenerated during the session, allowing multiple cycles of adsorption within a single treatment. This achieves a high degree of immunoglobulin depletion — typically reducing IgG levels by 70-90% per session.
Immunoadsorption is recommended based on specific laboratory findings and clinical presentation. Our physicians will determine suitability after thorough diagnostic evaluation.
A typical immunoadsorption session lasts 2-4 hours. The patient is seated or reclined in a comfortable treatment chair with venous access established. The apheresis machine processes the blood continuously while vital signs are monitored throughout. Most patients tolerate the procedure well, though mild fatigue or lightheadedness can occur. A course of treatment usually involves multiple sessions over several days, depending on the clinical indication.
Immunoadsorption is an established treatment in neurology, nephrology, and cardiology. Clinical studies have demonstrated its efficacy in autoimmune neurological conditions, with guidelines from the European Academy of Neurology and the American Society for Apheresis supporting its use in specific indications. The procedure has a well-characterized safety profile with a low rate of serious adverse events when performed in an experienced medical setting.
Contact our medical team to discuss whether immunoadsorption may be appropriate for your condition.
